申请人:Beecham Group p.l.c.
公开号:US04910307A1
公开(公告)日:1990-03-20
A process for the preparation of compounds of formula (I), and pharmaceutically acceptable salts thereof: ##STR1## wherein R.sub.1 is hydrogen or CH.sub.2 OH; R.sub.2 is hydrogen or, (when R.sub.1 is hydrogen), hydroxy or CH.sub.2 OH; R.sub.3 is CH.sub.2 OH or, (when R.sub.1 and R.sub.2 are both hydrogen), CH(OH)CH.sub.2 OH; R.sub.4 is hydrogen, hydroxy, amino or OR.sub.5 wherein R.sub.5 is C.sub.1-6 alkyl, phenyl or phenyl C.sub.1-2 alkyl either of which phenyl moieties may be substituted by one or two halo, C.sub.1-4 alkyl or C.sub.1-4 alkoxy groups; and in which any OH groups in R.sub.1, R.sub.2 and/or R.sub.3 may be in the form of O-acyl, phosphate, cyclic acetal or cyclic carbonate derivatives thereof; which process comprises the reaction of a compound of formula (II): ##STR2## wherein R.sub.4 ' is R.sub.4 or a group or atom convertible thereto and R.sub.x is amino or protected amino; with a compound of formula (III): R.sub.3 'CHR.sub.2 'CHR.sub.1 'Q (III) wherein Q is a leaving group and R.sub.1 ', R.sub.2 ' and R.sub.3 ' are R.sub.1, R.sub.2 and R.sub.3 respectively or R.sub.1, R.sub.2 and/or R.sub.3 wherein the OH group(s) is/are in protected form; and thereafter converting R.sub.4 ' when other than R.sub.4, to an R.sub.4 moiety or converting R.sub.4 ' when R.sub.4 to other R.sub.4 ; if necessary converting R.sub.1 ', R.sub.2 ' or R.sub.3 ' to R.sub.1, R.sub.1 and R.sub.3 respectively and optionally forming a pharmaceutically acceptable salt, O-acyl, phosphate, cyclic acetal or cyclic carbonate derivative thereof.
一种制备化合物(I)及其药用可接受盐的方法:其中R.sub.1为氢或CH.sub.2 OH;R.sub.2为氢或(当R.sub.1为氢时)羟基或CH.sub.2 OH;R.sub.3为CH.sub.2 OH或(当R.sub.1和R.sub.2都为氢时)CH(OH)CH.sub.2 OH;R.sub.4为氢、羟基、氨基或OR.sub.5,其中R.sub.5为C.sub.1-6烷基、苯基或苯基C.sub.1-2烷基,其中任一苯基团可能被一个或两个卤素、C.sub.1-4烷基或C.sub.1-4烷氧基取代;在其中R.sub.1、R.sub.2和/或R.sub.3中的任何羟基可以是其O-酰基、磷酸酯、环缩醛或环碳酸酯衍生物形式;该方法包括化合物(II)与化合物(III)的反应:其中R.sub.4'为R.sub.4或可转化为的基团或原子,R.sub.x为氨基或保护氨基;化合物(III)中的R.sub.3'CHR.sub.2'CHR.sub.1'Q(III),其中Q为脱离基团,R.sub.1'、R.sub.2'和R.sub.3'分别为R.sub.1、R.sub.2和R.sub.3或R.sub.1、R.sub.2和/或R.sub.3,其中羟基以保护形式存在;然后将R.sub.4'转化为非R.sub.4时的R.sub.4基团或将R.sub.4'转化为R.sub.4时的其他R.sub.4;如有必要,将R.sub.1'、R.sub.2'或R.sub.3'转化为R.sub.1、R.sub.1和R.sub.3,然后可选择形成药用可接受盐、O-酰基、磷酸酯、环缩醛或环碳酸酯衍生物。